-
1
-
-
14644435101
-
Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma
-
author reply 1044-1045
-
Altundag O, Altundag K, Gunduz E (2005) Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol 23: 1044; author reply 1044-1045
-
(2005)
J Clin Oncol
, vol.23
, pp. 1044
-
-
Altundag, O.1
Altundag, K.2
Gunduz, E.3
-
2
-
-
0037428774
-
Metastatic renal carcinoma comprehensive prognostic system
-
Atzpodien J, Royston P, Wandert T, Reitz M (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88: 348-353
-
(2003)
Br J Cancer
, vol.88
, pp. 348-353
-
-
Atzpodien, J.1
Royston, P.2
Wandert, T.3
Reitz, M.4
-
3
-
-
0026625812
-
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma
-
Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322
-
(1992)
Cancer Res
, vol.52
, pp. 3317-3322
-
-
Blay, J.Y.1
Negrier, S.2
Combaret, V.3
Attali, S.4
Goillot, E.5
Merrouche, Y.6
Mercatello, A.7
Ravault, A.8
Tourani, J.M.9
Moskovtchenko, J.F.10
Philip, T.11
Favrot, M.12
-
4
-
-
0030796001
-
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
-
Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72: 424-430
-
(1997)
Int J Cancer
, vol.72
, pp. 424-430
-
-
Blay, J.Y.1
Rossi, J.F.2
Wijdenes, J.3
Menetrier-Caux, C.4
Schemann, S.5
Negrier, S.6
Philip, T.7
Favrot, M.8
-
5
-
-
0034824273
-
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy
-
Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26: 797-808
-
(2001)
Psychoneuroendocrinology
, vol.26
, pp. 797-808
-
-
Capuron, L.1
Ravaud, A.2
Gualde, N.3
Bosmans, E.4
Dantzer, R.5
Maes, M.6
Neveu, P.J.7
-
6
-
-
33745141600
-
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
-
Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, George J, Bro WP, Kelly C, Bukowski R (2006) Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4: 191-199
-
(2006)
J Support Oncol
, vol.4
, pp. 191-199
-
-
Cella, D.1
Yount, S.2
Du, H.3
Dhanda, R.4
Gondek, K.5
Langefeld, K.6
George, J.7
Bro, W.P.8
Kelly, C.9
Bukowski, R.10
-
7
-
-
0037398224
-
Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator
-
Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15: 369-373
-
(2003)
Eur J Gastroenterol Hepatol
, vol.15
, pp. 369-373
-
-
Chung, Y.C.1
Chang, Y.F.2
-
8
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
Negrier, S.7
Chevreau, C.8
Solska, E.9
Desai, A.A.10
Rolland, F.11
Demkow, T.12
Hutson, T.E.13
Gore, M.14
Freeman, S.15
Schwartz, B.16
Shan, M.17
Simantov, R.18
Bukowski, R.M.19
-
9
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
10
-
-
0032901837
-
Pretreatment serum markers and lymphocyte response to interleukin-2 therapy
-
Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F (1999) Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 80: 407-411
-
(1999)
Br J Cancer
, vol.80
, pp. 407-411
-
-
Fumagalli, L.1
Lissoni, P.2
Di Felice, G.3
Meregalli, S.4
Valsuani, G.5
Mengo, S.6
Rovelli, F.7
-
11
-
-
0036269257
-
Therapeutic options in the management of renal cell carcinoma
-
Glaspy JA (2002) Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29: 41-46
-
(2002)
Semin Oncol
, vol.29
, pp. 41-46
-
-
Glaspy, J.A.1
-
12
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
DOI 10.1056/NEJMoa066838
-
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281 (Pubitemid 46849157)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
Staroslawska, E.7
Sosman, J.8
McDermott, D.9
Bodrogi, I.10
Kovacevic, Z.11
Lesovoy, V.12
Schmidt-Wolf, I.G.H.13
Barbarash, O.14
Gokmen, E.15
O'Toole, T.16
Lustgarten, S.17
Moore, L.18
Motzer, R.J.19
-
13
-
-
34548804499
-
C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: A European study of 313 patients
-
Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241-1247
-
(2007)
Cancer
, vol.110
, pp. 1241-1247
-
-
Karakiewicz, P.I.1
Hutterer, G.C.2
Trinh, Q.D.3
Jeldres, C.4
Perrotte, P.5
Gallina, A.6
Tostain, J.7
Patard, J.J.8
-
14
-
-
0141885298
-
Paraneoplastic signs and symptoms of renal cell carcinoma: Implications for prognosis
-
Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA (2003) Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170: 1742-1746
-
(2003)
J Urol
, vol.170
, pp. 1742-1746
-
-
Kim, H.L.1
Belldegrun, A.S.2
Freitas, D.G.3
Bui, M.H.4
Han, K.R.5
Dorey, F.J.6
Figlin, R.A.7
-
15
-
-
0028143097
-
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
-
Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J (1994) Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 98: 323-329
-
(1994)
Clin Exp Immunol
, vol.98
, pp. 323-329
-
-
Legouffe, E.1
Liautard, J.2
Gaillard, J.P.3
Rossi, J.F.4
Wijdenes, J.5
Bataille, R.6
Klein, B.7
Brochier, J.8
-
16
-
-
0031415831
-
Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma
-
Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33: 1794-1798
-
(1997)
Eur J Cancer
, vol.33
, pp. 1794-1798
-
-
Ljungberg, B.1
Grankvist, K.2
Rasmuson, T.3
-
17
-
-
0028885888
-
Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments
-
Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B (1995) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86: 3123-3131
-
(1995)
Blood
, vol.86
, pp. 3123-3131
-
-
Lu, Z.Y.1
Brailly, H.2
Wijdenes, J.3
Bataille, R.4
Rossi, J.F.5
Klein, B.6
-
18
-
-
0036583165
-
The role of C-reactive protein as a prognostic indicator in advanced cancer
-
Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250-255
-
(2002)
Curr Oncol Rep
, vol.4
, pp. 250-255
-
-
Mahmoud, F.A.1
Rivera, N.I.2
-
19
-
-
1442290393
-
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
-
Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463
-
(2004)
J Clin Oncol
, vol.22
, pp. 454-463
-
-
Motzer, R.J.1
Bacik, J.2
Schwartz, L.H.3
Reuter, V.4
Russo, P.5
Marion, S.6
Mazumdar, M.7
-
20
-
-
33846821872
-
Targeted therapy for metastatic renal cell carcinoma
-
Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608
-
(2006)
J Clin Oncol
, vol.24
, pp. 5601-5608
-
-
Motzer, R.J.1
Bukowski, R.M.2
-
21
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
22
-
-
2942756034
-
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie
-
Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 22: 2371-2378
-
(2004)
J Clin Oncol
, vol.22
, pp. 2371-2378
-
-
Negrier, S.1
Perol, D.2
Menetrier-Caux, C.3
Escudier, B.4
Pallardy, M.5
Ravaud, A.6
Douillard, J.Y.7
Chevreau, C.8
Lasset, C.9
Blay, J.Y.10
-
23
-
-
0028952405
-
Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
-
Finnish Leukemia Group
-
Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85: 765-771
-
(1995)
Blood
, vol.85
, pp. 765-771
-
-
Pelliniemi, T.T.1
Irjala, K.2
Mattila, K.3
Pulkki, K.4
Rajamaki, A.5
Tienhaara, A.6
Laakso, M.7
Lahtinen, R.8
-
24
-
-
77649172209
-
Pharmaco-kinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma
-
Puchalski T, Prabhakar U, Jiao T, Berns B, Davis HM (2010) Pharmaco-kinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16: 1652-1661
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1652-1661
-
-
Puchalski, T.1
Prabhakar, U.2
Jiao, T.3
Berns, B.4
Davis, H.M.5
-
25
-
-
34547384006
-
Hematological effects of in vivo blocking interleukin-6 (IL-6) with BE-8, a monoclonal antibody (MoAb) anti-IL-6
-
Rossi JF, Legouffe E, Blay JY, Fabbro M, Mousseau M, Khenifar B, Negrier S, Liautard J, Mao LQ, Racadot E, Wijdenes J, Philip T, Brochier J, Klein B (1992) Hematological effects of in vivo blocking interleukin-6 (IL-6) with BE-8, a monoclonal antibody (MoAb) anti-IL-6. Blood 80: 432a
-
(1992)
Blood
, vol.80
-
-
Rossi, J.F.1
Legouffe, E.2
Blay, J.Y.3
Fabbro, M.4
Mousseau, M.5
Khenifar, B.6
Negrier, S.7
Liautard, J.8
Mao, L.Q.9
Racadot, E.10
Wijdenes, J.11
Philip, T.12
Brochier, J.13
Klein, B.14
-
26
-
-
0344665774
-
Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: A single-center experience of 683 patients
-
Schips L, Lipsky K, Zigeuner R, Salfellner M, Winkler S, Langner C, Rehak P, Pummer K, Hubmer G (2003) Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology 62: 1024-1028
-
(2003)
Urology
, vol.62
, pp. 1024-1028
-
-
Schips, L.1
Lipsky, K.2
Zigeuner, R.3
Salfellner, M.4
Winkler, S.5
Langner, C.6
Rehak, P.7
Pummer, K.8
Hubmer, G.9
-
27
-
-
0033916898
-
Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis
-
Tanaka M, Kishimura M, Ozaki S, Osakada F, Hashimoto H, Okubo M, Murakami M, Nakao K (2000) Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest 106: 137-144
-
(2000)
J Clin Invest
, vol.106
, pp. 137-144
-
-
Tanaka, M.1
Kishimura, M.2
Ozaki, S.3
Osakada, F.4
Hashimoto, H.5
Okubo, M.6
Murakami, M.7
Nakao, K.8
-
28
-
-
0029780037
-
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop
-
van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH (1996) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 98: 1441-1448
-
(1996)
J Clin Invest
, vol.98
, pp. 1441-1448
-
-
Van Zaanen, H.C.1
Koopmans, R.P.2
Aarden, L.A.3
Rensink, H.J.4
Stouthard, J.M.5
Warnaar, S.O.6
Lokhorst, H.M.7
Van Oers, M.H.8
-
29
-
-
0031811798
-
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase i dose-escalating study
-
van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, van Oers MH (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 102: 783-790
-
(1998)
Br J Haematol
, vol.102
, pp. 783-790
-
-
Van Zaanen, H.C.1
Lokhorst, H.M.2
Aarden, L.A.3
Rensink, H.J.4
Warnaar, S.O.5
Van Der Lelie, J.6
Van Oers, M.H.7
-
30
-
-
0028896292
-
Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice
-
Weissglas M, Schamhart D, Lowik C, Papapoulos S, Vos P, Kurth KH (1995) Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 153: 854-857
-
(1995)
J Urol
, vol.153
, pp. 854-857
-
-
Weissglas, M.1
Schamhart, D.2
Lowik, C.3
Papapoulos, S.4
Vos, P.5
Kurth, K.H.6
-
31
-
-
34548208088
-
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis
-
Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12: 252-265
-
(2007)
Cancer Cell
, vol.12
, pp. 252-265
-
-
Yang, J.1
Wezeman, M.2
Zhang, X.3
Lin, P.4
Wang, M.5
Qian, J.6
Wan, B.7
Kwak, L.W.8
Yu, L.9
Yi, Q.10
-
32
-
-
3843139682
-
CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice
-
Zaki MH, Nemeth JA, Trikha M (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111: 592-595
-
(2004)
Int J Cancer
, vol.111
, pp. 592-595
-
-
Zaki, M.H.1
Nemeth, J.A.2
Trikha, M.3
|